Skip to main content
SpringerLink
Log in
Book cover

Hormone Therapy and Castration Resistance of Prostate Cancer pp 231–239Cite as

Enzalutamide Therapy for mCRPC in Japanese Men

  • Chapter
  • First Online:

  • 588 Accesses

Abstract

Enzalutamide, which inhibits androgen receptor signaling at multiple steps, was approved for metastatic castration-resistant prostate cancer (mCRPC) in Japan in 2014. Since then, we have treated mCRPC patients with enzalutamide; however, limited information is available as to clinical outcomes of enzalutamide in Japanese patients. In this chapter, I will review the efficacy, safety, and pharmacokinetics of enzalutamide in Japanese patients first from clinical trials, including the PREVAIL and phase I/II study in Japanese patients and then from retrospective studies of real-world data in Japan. Treatment effects and safety of enzalutamide in Japanese patients were generally consistent with the overall results from non-Japanese populations. However, in daily clinical practice, the patients often complain of such difficulties as swallowing due to the big size of capsule, fatigue, and appetite loss. In order to continue this effective enzalutamide therapy without discontinuation due to these subjective symptoms, dose reduction seems to be the best way.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Huggins C, Hodges CV. Studies on prostate cancer 1: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7.

    CAS  Google Scholar 

  2. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34–45.

    Article  CAS  PubMed  Google Scholar 

  3. Scher HI, Sawyers CL. Biology of progressive castration-resistant prostate cancer: directed therapies targeting the androgen- receptor signaling axis. J Clin Oncol. 2005;23:8253–61.

    Article  CAS  PubMed  Google Scholar 

  4. Montgomery RB, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Cai C, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011;71:6503–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Linja MJ, et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001;61:3550–5.

    CAS  PubMed  Google Scholar 

  7. Chen CD, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33–9.

    Article  PubMed  Google Scholar 

  8. Scher HI, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.

    Article  CAS  PubMed  Google Scholar 

  9. Beer TM, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Jung ME, et al. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem. 2010;53:2779–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Tran C, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Scher HI, et al. Antitumour activity of MDV3100 in castration- resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375:1437–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Beer TM, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71:151–4.

    Article  CAS  PubMed  Google Scholar 

  14. Kimura G, et al. Enzalutamide in Japanese patients with chemotherapy-naive, metastatic castration-resistant prostate cancer: a post-hoc analysis of the placebo-controlled PREVAIL trial. Int J Urol. 2016;23:395–403.

    Article  CAS  PubMed  Google Scholar 

  15. Akaza H, et al. A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer. Int J Clin Oncol. 2016;21:773–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Yamasaki M, et al. Efficacy and safety profile of enzalutamide for Japanese patients with castration-resistant prostate cancer. Anticancer Res. 2016;36:361–5.

    CAS  PubMed  Google Scholar 

  17. Igarashi A, et al. Initial experience of the enzalutamide treatment for castration-resistant prostate cancer. Jpn J Urol. 2016;107:155–61. (Japanese).

    Article  Google Scholar 

  18. Kato H, et al. Consequences of an early PSA response to enzalutamide treatment for Japanese patients with metastatic castration-resistant prostate cancer. Anticancer Res. 2016;36:6141–50.

    Article  CAS  PubMed  Google Scholar 

  19. Terada N, et al. Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study. Int J Clin Oncol. 2016;21:1155–61.

    Article  CAS  PubMed  Google Scholar 

  20. Iguchi T, et al. Management of enzalutamide-related adverse events for castration resistant prostate cancer patients. Jpn J Urol Surg. 2015;28:1685–91. (Japanese).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Nippon Medical School, Tokyo, Japan

    Go Kimura

Authors
  1. Go Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Go Kimura .

Editor information

Editors and Affiliations

  1. Department of Urology, Tohoku University School of Medicine, Sendai, Japan

    Yoichi Arai

  2. Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Osamu Ogawa

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kimura, G. (2018). Enzalutamide Therapy for mCRPC in Japanese Men. In: Arai, Y., Ogawa, O. (eds) Hormone Therapy and Castration Resistance of Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-7013-6_24

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-7013-6_24

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-7012-9

  • Online ISBN: 978-981-10-7013-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation